摘要
背景:术语酒精使用障碍(AUD)包含与经常使用酒精有关的不同疾病状态,并与相关的损害、残疾和未能在不同领域承担主要责任有关。许多神经递质系统都参与了酒精中毒的阶段或状态,从奖赏机制,与狂饮,到压力和焦虑,与复发和戒断有关。一些神经肽在焦虑和应激的控制中起着关键作用,并与酒精成瘾的病理机制建立密切的关系。其中,神经肽Y(NPY),促肾上腺皮质激素释放因子(CRF)/尿皮质激素和神经肽(NPS)的交叉对话,对大脑在疾病进展过程中出现的一些不适应过程负责。 方法:在本研究中,我们回顾文献主要关注这些神经肽在AUD的病理生理学中的参与,以及用于研究在配体结合后启动的信号机制以及与酒精上瘾相关的生物化学适应事件的拮抗剂的使用。也讨论了这些系统作为治疗目标以减轻或消除饮用乙醇所产生的危害的可能性。 结论:本文综述的多肽系统与其他神经递质系统以及它们的相互关系,都是对AUD治疗的目标。
关键词: 酒精使用障碍(AUD),酒精中毒,神经肽Y,皮质激素释放因子(CRF),神经肽S(NPS),尿皮质I,神经肽拮抗剂。
Current Medicinal Chemistry
Title:Targeting NPY, CRF/UCNs and NPS Neuropeptide Systems to Treat Alcohol Use Disorder (AUD)
Volume: 24 Issue: 23
关键词: 酒精使用障碍(AUD),酒精中毒,神经肽Y,皮质激素释放因子(CRF),神经肽S(NPS),尿皮质I,神经肽拮抗剂。
摘要: Background: The term Alcohol Use Disorder (AUD) incorporates different states of disease related to the recurrent use of alcohol and linked to the relevant impairment, disability and failure to perform major responsibilities in different realms. Many neurotransmitter systems are involved in the phases or states of alcoholism from reward mechanisms, associated to binge intoxication, to stress and anxiety linked to relapse and withdrawal. Some neuropeptides play a key function in the control of anxiety and stress, and establish a close relationship with the pathological mechanisms underlying alcohol addiction. Among them, Neuropeptide Y (NPY), Corticotropin-releasing factor (CRF)/Urocortins and Neuropeptide S (NPS) cross-talk, and are responsible for some of the maladaptation processes that the brain exhibits during the progression of the disease.
Method: In this study, we review the literature mainly focused on the participation of these neuropeptides in the pathophysiology of AUD, as well as on the use of antagonists designed to investigate signaling mechanisms initiated after ligand binding and their connection to biochemical adaptation events coupled to alcohol addiction. The possibility that these systems may serve as therapeutic objectives to mitigate or eliminate the harm that drinking ethanol generates, is also discussed. Conclusion: The peptide systems reviewed here, together with other neurotransmitter systems and their mutual relationships, are firm candidates to be targeted to treat AUD.Export Options
About this article
Cite this article as:
Targeting NPY, CRF/UCNs and NPS Neuropeptide Systems to Treat Alcohol Use Disorder (AUD), Current Medicinal Chemistry 2017; 24 (23) . https://dx.doi.org/10.2174/0929867324666170316120836
DOI https://dx.doi.org/10.2174/0929867324666170316120836 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gonioprobe, an Innovative Gamma-probe to Guide Parathyroid Radioguided Surgery: First Clinical Experiences with Navigator and Lock-ontarget Functions
Current Radiopharmaceuticals Increased Tumor Oxygenation and Drug Uptake During Anti-Angiogenic Weekly Low Dose Cyclophosphamide Enhances the Anti-Tumor Effect of Weekly Tirapazamine (Supplementry Material)
Current Cancer Drug Targets Association of Neutrophil-Lymphocyte Ratio with Mild Cognitive Impairment in Elderly Chinese Adults: A Case-control Study
Current Alzheimer Research TGF-β Signal Transduction in Pancreatic Carcinoma Cells is Sensitive to Inhibition by the Src Tyrosine Kinase Inhibitor AZM475271
Anti-Cancer Agents in Medicinal Chemistry Predictive Markers for Haematological Toxicity of Pemetrexed
Current Drug Targets Editorial [Hot Topic: When Can a Drug be Declared “Safe”? (Guest Editors: Frank M.C. Besag & Seetal Dodd)]
Current Drug Safety Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes
Current Drug Metabolism Vitamin D/VDR, Probiotics, and Gastrointestinal Diseases
Current Medicinal Chemistry Regulation of Iron Absorption in Hemoglobinopathies
Current Molecular Medicine Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Large Granular Lymphocyte (LGL) Leukemia: Pathobiology, Diagnosis and Treatment
Current Cancer Therapy Reviews CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Lipidomic Analysis of Glioblastoma Multiforme Using Mass Spectrometry
Current Metabolomics Tetracyclines: Drugs with Huge Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Polyphenols from Red Wine Modulate Immune Responsiveness: Biological and Clinical Significance
Current Pharmaceutical Design Biomarkers and Novel Therapeutic Targets in Gastrointestinal Stromal Tumors (GISTs)
Recent Patents on Anti-Cancer Drug Discovery Ulcerative Colitis: Pathogenesis
Current Drug Targets The Psychopharmacology of Appetite: Targets for Potential Anti-Obesity Agents
Current Medicinal Chemistry - Central Nervous System Agents Dendrimers as Novel Systems for Delivery of Neuropharmaceuticals to the Brain
CNS & Neurological Disorders - Drug Targets Cognitive Remediation in the Early Course of Schizophrenia: A Critical Review
Current Pharmaceutical Design